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Myelin basic protein (MBP) is a major candidate autoantigen in
multiple sclerosis (MS). Its immunodominant epitope, MBP 85–99,
forms a complex with human leukocyte antigen (HLA)-DR2 with
which multiple sclerosis is genetically associated. Copolymer 1
(Copaxone), a random amino acid copolymer [poly (Y,E,A,K)n] as
well as two modified synthetic copolymers [poly (F,Y,A,K)n and
poly (V,W,A,K)n] also form complexes with HLA-DR2 (DRA
DRB1*1501) and compete with MBP 85–99 for binding. Moreover,
two high-affinity synthetic peptide 15-mers that could inhibit
binding even more effectively were previously designed. Here, we
show that further-modified peptide 15-mers inhibited even more
strongly (in order J5 > J3 > J2) both the binding of MBP 85–99 to
HLA-DR2 and IL-2 production by two MBP 85–99-specific HLA-DR2-
restricted T cells. J5, J3, and J2 also suppressed both MBP 85–99-
induced experimental autoimmune encephalomyelitis (EAE) in hu-
manized mice and proteolipid protein 139–151-induced EAE in
SJLJ mice. Moreover, none of these previously uncharacterized
peptide inhibitors crossreacted with MBP 85–99- or proteolipid
protein 139–151-specific T cells. In both cases, spleen and lymph
node cultures stimulated with these peptides produced large
amounts of Th2 cytokines (IL-4 and IL-10), and adoptive transfer of
established T cell lines suppressed disease induction. These peptide
15-mers provide specific, nonrandom sequences that appear to be
at least as effective as random copolymers in suppressing EAE in
several models.
Cop1  HLA-DR  multiple sclerosis  T cells
Multiple sclerosis (MS), an autoimmune inflammatory dis-ease of the CNS, is associated with the HLA-DR2 hap-
lotype (DRA*0101, DRB1*1501, DQA1*0102, DQB1*0602)
(1–3). Myelin basic protein (MBP) is one of the major candidate
autoantigens in the pathogenesis of MS. Particularly, T cell
reactivity to the immunodominant MBP 85–99 epitope is found
in subjects carrying human leukocyte antigen (HLA)-DR2, a
genetic marker for susceptibility to MS. HLA-DR2-restricted
MBP-specific T cells are clonally expanded and activated in MS
patients (4–9). Furthermore, HLA-DR2MBP 85–99 complexes
have been detected in the CNS plaques of these patients (10).
Critical residues for binding to HLA-DR2 and for T cell antigen
receptor (TCR) recognition of the MBP 85–99 epitope have
been defined (11, 12).
Several therapeutic approaches to MS have been attempted by
using cytokines, copolymers, dimers of class II major histocom-
patibility complex-peptide complexes, peptide antigens that
induce anergy, vaccination with TCR, and an altered peptide
ligand (13–19). Many of these studies aimed to interfere with the
MBP 85–99-specific T cell recognition andor to deviate the T
cell response from the Th1 to the Th2 phenotype. Copolymer 1
[Cop1, Copaxone, Glatiramer Acetate, poly(Y, E, A, K)n], the
only approved drug known to reduce MBP-specific T cell
responses, reduces the relapse rate by 30% in relapsing-
remitting forms of MS (20–26). Cop1 binds to several human
HLA-DR molecules, including HLA-DR2, and blocks modestly
the presentation of MBP 85–99 (27, 28). The effectiveness of
amino acid copolymers with in vitro and in vivo assays was greatly
improved by modifications that enhanced their binding to HLA-
DR2 (29, 30). We hypothesized that by similarly improving the
binding of synthetic peptide mimetics (13, 29, 30), their effec-
tiveness might also be greatly enhanced. Thus, T cell recognition
of MBP 85–99 might be more effectively inhibited andor
additional immunosuppressive functions of the copolymers
might be enhanced by the peptide mimetics. In this paper we
report generation of three peptide inhibitors based on the
binding motif of MBP 85–99 to HLA-DR2 with improved
functions in inhibiting T cell responses and experimental auto-
immune encephalomyelitis (EAE). These 15-mers (J2, J3, and
J5) competed with MBP 85–99 for binding to HLA-DR2,
inhibited IL-2 secretion by MBP 85–99-specific T cell clones and
induced production of Th2 cytokines by splenocytes. Addition-
ally they did not crossreact with MBP 85–99- or PLP 139–151-
specific T cells. They also suppressed EAE in two different
murine disease models in a manner equivalent to that achieved
by using the modified random amino acid copolymers.
Materials and Methods
Generation of Peptide-Specific Short-Term T Cell Lines and Prolifer-
ative Responses to Peptides. Mice were immunized with proteo-
lipid protein (PLP) 139–151 or peptide 15-mers (100 g per
mouse) emulsified in complete Freund’s adjuvant (CFA)
(Difco). Ten days later, single-cell suspensions were prepared
from spleens and lymph nodes and they were stimulated with
corresponding peptides at a concentration of 10 gml in the
presence of antigen-presenting cells. After two rounds of re-
stimulation, viable lymphocytes were separated by Ficoll
Hypaque density gradient centrifugation and used to test their
specificity at a dose range of 0–50 gml. As a negative control,
Nase 101–120 peptide, which also binds I-As, was used. To
determine the proliferative response of transgenic (tg) T cells
expressing the HLA-DR2-restrictedMBP 85–99-specific TCR
(hV2CD4) and non-tg T cells (hV2CD4), splenocytes
were fractionated from double-tg humanized mice that express
both HLA-DR2 and a MBP 85–99-specific hV2 T cell receptor
from an MS patient (30) by flow cytometry and seeded into a
96-well U-bottom microtiter plate in complete medium at 4 
105 cells per well. Irradiated splenocytes of humanized mice, also
expressing HLA-DR2, were used as antigen-presenting cells.
Cultures were stimulated with 10 gml of MBP 85–99 or 100
Abbreviations: CFA, complete Freund’s adjuvant; EAE, experimental autoimmune enceph-
alomyelitis; HLA, human leukocyte antigen; MBP, myelin basic protein; MS, multiple
sclerosis; PLP, proteolipid protein; TCR, T cell antigen receptor; tg, transgenic.
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gml peptides J2, J3, or J5). Proliferative responses were
measured as described in refs. 17 and 29.
Effect of Peptide 15-mers on the Induction of EAE. Female SJLJ or
humanized mice were immunized s.c., each with 50 g of PLP
139–151 or 150g MBP 85–99 alone, or coimmunized with these
antigens and 150 g peptide 15-mers emulsified in CFA. Per-
tussis toxin, 150 ng (List Biological Laboratories, Campbell,
CA), was given for humanized mice 8–12 weeks old i.p. on the
day of immunization and on day 2 postimmunization and for
SJLJ mice i.v. on day 2 only. The mice were monitored for
appearance of EAE and scored from 0–5 as described in refs. 17,
29, and 30.
Adoptive Transfer of Peptide-Specific T Cell Lines. SJLJ mice were
immunized with either 50 g of PLP 139–151 peptide or 250 g
of peptides J2, J3, or J5. Cell lines were prepared and used as
described in refs. 17 and 29.
Additional Materials or Methods. Additional materials or methods
included mice (17, 29, 30), peptide synthesis (13), isolation of
empty HLA-DR2 (12, 13), inhibition by peptide 15-mers of MBP
85–99 binding to HLA-DR2 (DRADRB1*1501) (13, 17), sort-
ing of tg and endogenous (non-tg) T cells from humanized mice
by flow cytometry (30), cytokine measurement by ELISA (30),
and detection of PLP 139–151-reactive CD4 T cells by using
I-AsPLP 139–151 tetramers (31, 32).
Results
Design of Synthetic Peptide 15-mers. The design of the peptide
15-mers was based on the following criteria: (i) MBP 85–99 has
V89 at P1 and F92 at P4. (ii) Y at the P1 of peptides or
copolymers (as found in Copolymer 1) is too large for the P1
pocket. Such peptides (as used in ref. 13) are, therefore, poor
binders to HLA-DR2. F at P1 of MBP 85–99 was less effective
than V in a T cell stimulation assay (11, 17). (iii) A peptide with
the large hydrophobic amino acid W substituted for F at P4 of
MBP 85–99 was found to effectively stimulate a HLA-DR2-
restricted T cell clone (11, 12). Moreover, in the binding motif
of Cop1 to HLA-DR2, Y was eluted from the P4 pocket (28).
Here, both the P1 and P4 residues of the previously described
15-mers nos. 100 and 101 (13) (J1 and J11 in Table 1) were
therefore substituted with hydrophobic amino acids of different
sizes V, F, or Y. (iv) K at P5, the major TCR contact residue in
MBP 85–99, was retained in all peptides. (v) Further, the
residues at P6 to P11 in MBP 85–99 were substituted by alanine,
except that in some peptides, proline was placed at the penul-
timate position P10 because proline residues are resistant to
exopeptidases in serum. For the purpose of in vivo EAE studies,
P at P2 (as found in MBP 85–99) and at P5 were also included
in some peptides for the same reason. These prolines did not
change the binding affinity of peptides for HLA-DR2 (Table 1).
(vi) The TCR contact site V88 of MBP 85–99 at P1 (12) was
substituted by lysine; this modification was hypothesized to
enhance binding to HLA-DR2 (13). All of these peptide ana-
logues were designed to achieve a minimum possible homology
with MBP 85–99, yet bind to HLA-DR2 with high affinity and
retain K at P5.
Inhibition of Binding of MBP 85–99 to HLA-DR2 (DRADRB1*1501) by
Synthetic Peptides. To examine whether the peptides competed
with the immunodominant epitope MBP 85–99 for binding to
HLA-DR2 molecules, competitive binding studies were per-
formed. Several peptides inhibited binding of biotinylated MBP
85–99 to HLA-DR2 molecules very efficiently (Table 1). The
most effective peptides were J3, J5, J8, J9, J13, J15, and J17. All
of these had V or F at P1 and Y or F at P4. Strikingly, placing
E at P1 as a control significantly decreased binding (J4 and J6).
Notably, Cop1, which contains E as well as Y, had a lower
binding affinity for HLA-DR2 and inhibited binding of biotin-
ylated MBP 85–99 less efficiently than the peptides (Table 1).
The data obtained for peptides J2-J10, all based on J1 (no. 100),
were very similar to those for J12-J17 based on J11(no. 101).
Further evaluation was focused on J1-J5. J3 and J5 showed
maximum inhibition of MBP 85–99 binding to HLA-DR2,
particularly at lower concentrations (Fig. 1A).
Inhibition by Synthetic Peptide 15-mers of IL-2 Secretion by an
HLA-DR2-Restricted, MBP 85–99-Specific T Cell Hybridoma. The fact
that the peptides competed with MBP 85–99 in binding to
HLA-DR2 provided a basis to test the hypothesis that they also
inhibit MBP-specific T cells. The T cell hybridoma 8073 that had
been transfected with the MBP 85–99-specific TCR from clone
Ob1A.12, derived from a HLA-DR2 patient with relapsing-
remitting MS (33), was used. The parent peptide J1, J2, J3, and
J5 completely inhibited MBP 85–99-induced IL-2 secretion (as
measured by proliferation of the IL-2-responsive CTLL line) by
hybridoma 8073 in a dose-dependant manner (Fig. 1B). This
inhibition was significantly greater than the effect of either Cop
1 or J4 (Fig. 1B) (P  0.05). J5 was the best inhibitor, as well as
binder, suggesting that the V at P1 and Y at P4 were critical for
enhanced binding of these peptides to HLA-DR2. Inhibition by
the peptides of IL-2 production by the 2E12 T cell line obtained
from a double-tg humanized mouse (33) was comparable to that
obtained with the 8073 T cell hybridoma (data not shown).
Table 1. Percent inhibition of binding of MBP 85–99-bio at 0.3
M by peptide competitor at 1 M
The parent compounds J1 and J11 (13) are in italics. Modifications are
shown in bold.
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Synthetic Peptide 15-mers Are Immunogenic. To examine immuno-
genicity of the synthetic peptides, humanized mice (30) were
immunized with 100 g each of J2, J3, J5, and MBP 85–99.
Spleen and lymph node cells were collected 10 days later and
restimulated in vitro with the corresponding peptides to generate
cell lines. As expected, MBP 85–99 elicited a strong proliferative
response of the line that was generated by using this antigen (Fig.
2A Left). Likewise, in the mice immunized with J3 or J5 alone
a lower response was induced suggesting, by analogy to responses
to copolymers (30), that the non-tg, endogenous T cells (that
represent 70% of the T cells in the humanized mice) might
have responded to these peptides presented by HLA-DR2.
However, a negligible response to J2 (that bound weakly) was
seen. Immunogenicity of these peptides was further verified in
SJLJ mice (in which I-As in the only expressed class II major
histocompatibility complex protein) and compared with PLP
139–151, one of the most immunodominant and encephalito-
genic epitopes of PLP in SJLJ mice (34, 35). SJLJ mice
immunized with these peptides were able to elicit proliferative
response after restimulation by peptide 15-mers J2, J3, and J5
(Fig. 2A Right). Thus, the peptides are able to bind to both
HLA-DR2 and I-As and induce peptide-specific T cells.
Peptide 15-mer-Reactive T Cell Lines Do Not Crossreact with Those of
MBP 85–99. Based on previous work with copolymers (29), tg T cells
(30% of the T cells) were assumed to be the main responders to
MBP 85–99 in humanized mice with a smaller response of the
endogenous T cells. Therefore, MBP 85–99-specific tg
(hV2CD4) and endogenous, non-tg (hV2CD4) T cells
were sorted by flow cytometry from spleen cells of double-tg
humanized mice. Both sets were stimulated with 10 gml MBP
Fig. 1. Peptides J1-J5 inhibit binding of MBP 85–99 to HLA-DR2 (DRA
DRB1*1501) and inhibit proliferation of MBP 85–99 T cells. (A) Competitive
binding. Recombinant HLA-DR2 molecules were incubated with 0.13 M
biotinylated MBP 85–99 alone or in the presence of unlabeled MBP 85–99 or
peptides J1-J5 (1–100 M). The reaction mixtures were transferred to the
plates coated with mAb LB3.1 that binds HLA-DR2 molecules and incubated
for 55 min, followed by removal of the supernatant. Streptavidin-conjugated
alkaline phosphatase and its substrate were added and incubated for 55 min.
The absorbance was measured at 450 nm by using a microtiter plate reader. (B)
Proliferation inhibition. Irradiated MGAR cells (HLA-DR2 homozygous) as
antigen-presenting cells were coincubated with MBP 85–99 (12.5 M) and
various concentrations of the peptides J2, J3, or J5 or Cop1 for 2 h. MBP
85–99-specific T cell hybridoma 8073 were then added and the mixtures
incubated for 24 h. Culture supernatants were used to test the proliferative
response of IL-2-dependent CTLL, and the response was measured as cpm 16 h
after pulsing with 3[H]thymidine.
Fig. 2. Generation, cross-reactivity, and cytokine production of T cells were
examined (A) Peptides J2, J3, and J5 are immunogenic. Humanized (Left) or
SJLJ (Right) mice were immunized with MBP 85–99 or PLP 139–151, respec-
tively, or peptides J2, J3, and J5 (100g in CFA). After 10 days, splenocytes were
restimulated three times at 2-week intervals with the corresponding peptides
at 10gml in the presence of irradiated antigen-presenting cells. Two weeks
later, viable cells were stimulated with corresponding peptides for two days.
Sixteen hours after pulsing with 3[H]thymidine, proliferative response was
measured as cpm. (B) J2, J3, and J5 do not stimulate MBP 85–99- or PLP
139–151-specific T cells. (Left) MBP 85–99-specific tg and endogenous (non-tg)
cells from humanized mice were sorted by flow cytometry and cultured with
MBP 85–99 or peptides J2, J3, or J5 at 50 gml. Their proliferative response
was measured as cpm after pulsing with 3[H]thymidine. (Right) PLP 139–151-
specific T cells were incubated with PLP 139–151 or peptides J2, J3, or J5, and
the proliferative response was measured as cpm after pulsing with 3[H]
thymidine. (C) Peptides J2, J3, and J5 induce T cells that produce Th2, but not
Th1, cytokine responses. SJLJ mice were immunized with either PLP 139–151
or peptides J2, J3, or J5 as described in Materials and Methods. After 10 days,
single-cell suspensions derived from lymph nodes and spleens were restimu-
lated with the corresponding peptides in the presence of antigen presenting
cells for 2 days. Culture supernatants were examined for secretion of IL-2, IL-4,
IL-10, and IFN- by ELISA.
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85–99 or 100 gml of J2, J3, or J5 in the presence of irradiated
syngeneic splenocytes. MBP 85–99 efficiently stimulated the tg
CD4 T cells to an extent significantly higher than that obtained
from endogenous CD4 cells (Fig. 2BLeft). By contrast, J2, J3, and
J5 did not induce proliferation of either MBP 85–99-specific tg or
endogenous CD4 cells, confirming that these peptides do not
crossreact with this human MBP 85–99-specific TCR or with the
nonclonal endogenous TCR that respond to MBP 85–99 (Fig. 2B).
The lack of response to J2, J3, or J5 was not due to cell death
because in all of the treatment groups, viable cell numbers were
comparable (data not shown).
Lack of cross-reactivity to these peptides was further verified by
using a PLP 139–151-specific cell line. This line responded only to
PLP 139–151 and neither to the control peptide NASE 101–120 nor
to J2, J3, or J5 (Fig. 2B Right). Similarly, T cell lines derived from
SJLJ mice immunized with J2, J3, or J5 responded only to the
cognate peptide and not to PLP 139–151 (data not shown).
Peptide 15-mer-Specific T Cells Produce Th2 Cytokines Preferentially.
The cytokine profiles of short-term lines stimulated with J2, J3, or
J5 were compared with those of PLP 139–151-stimulated cultures.
SJLJ mice were immunized with PLP 139–151, J2, J3, or J5 in CFA
and, after 10 days, spleen and lymph node cells were stimulated with
their cognate peptides in the presence of irradiated antigen-
presenting cells for 2 days (see Materials and Methods). In cultures
stimulated with PLP 139–151, IL-2 and IFN- were produced in
significant amounts, whereas neither was produced in those stim-
ulated with the peptide 15-mers (Fig. 2C). In contrast, IL-10
production was dominant in cultures stimulated with peptides J3
and J5 in amounts3-fold higher than in those stimulated with PLP
139–151 or peptide J2. Secretion of IL-4 was comparable in all of
the cultures regardless of peptide used.
J2, J3, and J5 Ameliorate EAE Induced byMBP 85–99 in HumanizedMice
or PLP 139–151 in SJLJ Mice. The ability of J2, J3, and J5 to
ameliorate the severity of EAE in vivo was tested in two models of
EAE: (i) MBP 85–99-induced EAE in HLA-DR2 and MBP
85–99-specific TCR double-tg humanized mice or (ii) PLP 139–
151-induced EAE in SJLJ mice. In the first model, the humanized
mice, after immunization with MBP 85–99, all mice in the group
developed clinical signs of EAE between days 6 and 9 (Fig. 3A).
Although one mouse died, the remaining mice reached a mean
maximum score of 2.5 and then entered a chronic phase of the
disease with a mean of 2.0. On the other hand, in the mice
coimmunized with the J2, J3, or J5 and MBP 85–99, the onset of
disease was delayed by 2–5 days, and the disease severity was
strikingly reduced during the acute phase of EAE. The maximum
mean scores of J2-, J3-, and J5-treated mice were 1 (limp tail).
Importantly, no mortalities occurred in any of the coimmunized
groups. In a previous study, Cop1 reduced the signs of EAE but less
effectively (30). In the second model, EAE was induced in SJLJ
mice by immunizing with PLP 139–151. The first sign of EAE
appeared at day 7 and reached a maximum mean score of 3 by day
16 (Fig. 3B). Three of the eight mice immunized with PLP 139–151
died. In parallel, groups of six mice were coimmunized with Cop 1
or with J2, J3, and J5 together with PLP 139–151. In the mice
coimmunized with Cop 1, the severity of EAE was moderately
suppressed (mean maximum score 2.5 at about day 22, followed by
slow recovery) (see Fig. 5B). By contrast, mice coimmunized with
J2, J3, or J5 developed only a mild disease (mean clinical score1).
No mortalities occurred in any of these groups. Thus, the severity
of EAE in J2, J3, or J5 coimmunized groups was significantly lower
than in mice immunized with PLP 139–151 or coimmunized with
Cop 1.
Suppression by Adoptive Transfer of Peptide-Specific T Cell Lines.
SJLJ mice were immunized s.c. with either 50 g of PLP 139–151
or 250 g of J2, J3, or J5. On day 10, splenocytes were restimulated
three times in vitro every other week with peptide-pulsed irradiated
splenocytes from naı¨ve mice. After the third round of stimulation,
92% of the cells present in all of the cultures were CD3 T cells.
Then, 5  106 T cells of the J2, J3, or J5 stimulated cultures were
administered i.v. per mouse. EAE was induced the next day by using
PLP 139–151 in CFA. Compared with PLP 139–151 controls, all of
the mice that received peptide-specific T cells had a delayed onset
of a much milder form of EAE (Fig. 4).
Peptide 15-mers Inhibit the Expansion of PLP 139–151-Specific T Cells.
To determine whether J2, J3, and J5 affect the expansion of
antigen-specific T cells, I-AsPLP 139–151 tetramers were used.
Fig. 3. Peptide 15-mers reduce severity of EAE. EAE was induced in human-
ized or SJLJ mice by immunizing with MBP 85–99 (150g) (A) or PLP 139–151
(50 g) (B), respectively, with or without peptides J2, J3, or J5 (100 g) or Cop
1 (150 g) (see Materials and Methods). Appearance of clinical signs of EAE
was monitored daily, and the disease severity was scored. This data represent
the average of three experiments. Cop1 was not included in the MBP 85–99
experiment because of a limitation in the availability of humanized mice, but
its effect is shown in figure 2A of ref. 29. P values vs. MBP 85–99 on day 16 (n
8 per group): J2;0.001; J3,0.01; J5,0.008; vs. PLP 139–151 on day 22 (n
7 per group): J2, 0.008; J3, 0.005; J5, 0.002; vs. Cop1: J2; 0.11; J3, 0.05;
J5, 0.03. Each experiment was performed three times.
Fig. 4. Suppression of EAE upon adoptive transfer of peptide-specific T cell
lines. Peptide-specific T cells (5  106) from lines established after immuniza-
tion with J2, J3, or J5 alone were transferred into naı¨ve SJLJ mice, and then,
on the next day, the mice were immunized s.c. with 50 g of PLP 139–151 in
CFA. Appearance of clinical signs of EAE was monitored daily and the disease
severity was scored. P values vs. control on day 22 (n  9 per group): J2,
0.0005; J3, 0.0003; J5, 0.0001. Experiment performed twice.
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Lymphocytes from SJL mice either immunized with PLP 139–151
or coimmunized with the peptides and PLP 139–151 were cultured
with PLP 139–151 for 4 days. As expected, SJL mice immunized
with PLP 139–151 led to the expansion of PLP tetramer reactive
cells (1.5%), and the response was specific because there was no
response to Theiler’s murine encephalomyelitis virus (TMEV)
control tetramers (Fig. 5). In striking contrast, expansion of PLP
139–151-specific T cells was reduced markedly in mice coimmu-
nized with peptides J5 or J2 and PLP 139–151.
Discussion
Peptides of 15 amino acids in length were previously designed
based on the crude binding motif of Copolymer 1 to HLA-DR2
(13). About 120 peptides were synthesized and assayed for their
ability to compete with MBP 85–99 for binding to HLA-DR2 and
for inhibition of proliferation of two T cell hybridomas that carry
the TCR derived from two different MS patients (13). Among
the peptides synthesized, two peptides (nos. 100 and 101 in ref.
13, J1 and J11 in this article) were unusually active in both assays.
These peptides were identical to MBP 85–99 at only two residues,
but notably they both retained K at P5, the dominant T cell
stimulatory residue (11, 12) and had a large hydrophobic amino
acid Y at both of the putative anchor residues P1 and P4.
This study is an effort to improve the binding affinity of these
peptides for HLA-DR2 based on the knowledge of how peptides
bind to this protein (11, 12) while retaining their ability to inhibit
proliferation of encephalitogenic T cell clones in vitro, but more
importantly, to test these peptides in in vivo assays of amelioration
of EAE in mice and to study their mechanisms. The following
modifications have been made. Peptides J1 and J11 have Y at P4,
which is well accommodated in the large hydrophobic P4 pocket of
HLA-DR2 (Table 1). However, they also have Y at the putative P1
position, which is too large for the P1 pocket. This small dimorphic
pocket is formed in part by 86V (rather than86G) of HLA-DR2,
although Y can be forced into it at high concentrations. Thus, V,
which is found at P1 in MBP 85–99, and F, which may just fill the
P1 pocket, were systematically substituted at this position. Two
peptides, J4 and J6, contained E at the putative P1 position; the
negative charge of E precluded binding to HLA-DR2, and they
served as controls. Finally, P found as P87 (P2) in MBP 85–99 was
added at this position in some peptides or at the very beginning of
the peptide (P5) as well as at the penultimate 14th residue (P10),
in the hope that it might prevent degradation by aminopeptidases
and carboxypeptidases found in serum. In some peptides, Y at the
putative P4 position was substituted by F; the very large hydropho-
bic P4 pocket of HLA-DR2 can accommodate F, Y, or even W (11).
Most of the peptides inhibited binding of biotinylated MBP 85–99
to some extent as did Cop1 (Fig. 1A and Table 1). However, several
stood out as inhibiting binding much better than the others,25%
at the lowest concentration tested, and were far more effective in
competing with biotinylated MBP than either MBP 85–99 itself or
particularly Cop1. These same peptides were also the best at
inhibiting proliferation of the T cell hybridomas (Fig. 1B). However,
this assay was compromised by the high value (presumably a blank
value) shown by both peptides J4 and J6. These peptides served as
negative controls and did not bind at all to HLA-DR2 at the highest
concentrations tested.
Because the group of peptides based on peptide J1 and J11 gave
similar data, only the first group was evaluated in vivo. J2 (the
proline substituted derivative of J1) and both J3 and J5 (also with
proline substitutions and with F or V at P1, respectively) were
preferentially examined. Two different mouse strains were used.
SJLJ mice bear I-As as the only class II major histocompatibility
complex protein, whereas in the humanized mouse, all murine class
II genes have been knocked out and replaced by DRA and
DRB1*1501 that encode HLA-DR2. In addition, this mouse bears
as a transgene the TCR from an MS patient (the same TCR that
is present in the 8073 T cell hybridoma). These mice were immu-
nized with peptide MBP 85–99 (humanized mouse) or PLP 139–
151 (SJLJ mouse). Splenocyte lines were established by stimula-
tion with these same peptides or with peptides J2, J3, or J5.
Proliferative responses of these lines to each of the immunogens
were obtained (except in the case of the line established from the
humanized mouse with the J2 peptide, in which case proliferation
was very weak) (Fig. 2A). Notably, the T cell lines that responded
to PLP 139–151 or sorted tg cells that responded to MBP 85–99 did
not crossreact with any of the peptides J2, J3, and J5 or with Cop1
(Fig. 2B). The lines established after immunization with J2, J3, or
J5 produced the Th2 cytokines IL-4 and IL-10 but notably not the
Th1 cytokines IFN- and IL-2 that were produced by PLP 139–
151-specific lines (Fig. 2C). The peptides were also remarkably
effective in the amelioration of EAE in both mouse models in
comparison with Cop1 (Fig. 3), and adoptive transfer of peptide
specific cell lines strongly suppressed the subsequent induction of
EAE by PLP 139–151 with effectiveness in order of J5  J3 
J2-specific lines (Fig. 4). Additionally, in SJLJ mice, the synthetic
peptides, particularly J2 and J5, prevented the expansion of PLP
139–151-specific CD4 cells in vitro (Fig. 5). These effects essentially
reproduce those previously found by using random amino acid
copolymers (29, 30).
Previously, an altered MBP 85–99 was designed by the sub-
stitutions E85A(D-Ala), N86K, F91L, and K93A in MBP 85–99
(using the numbering as in Table 1) (36), after an earlier study
of single alanine substitution (37). This altered peptide ligand
was shown to be effective in binding to HLA-DR2 molecules and
Fig. 5. Peptide 15-mers suppress proliferation of PLP 139–151-specific CD4
T cell responses. SJLJ mice were immunized with PLP 139–151 in CFA. After 10
days, lymphocytes from axillary and inguinal lymph nodes were cultured with
PLP 139–151 alone or PLP 139–151 together with J2, J3, or J5 (Left) at 10
gml. Four days later, viable lymphoblasts were incubated with I-As tetram-
ers [PLP 139–151 or TMEV 70–86 (Right)] for 3 h, as described in ref. 32. The
I-Astetramer-stained cells were determined in the live CD4T cell subset after
eliminating dead cells (7-AAD positive).
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also therapeutically proved beneficial in an animal model of MS
(38). However, contrary to expectation, the altered peptide
ligand exacerbated the clinical signs of MS, an effect attributed
to cross-reactivity with MBP 85–99 (39).
Induction of EAE is mediated by Th1 cells, and IFN- is an
important mediator of encephalomyelitis (40, 41). On the other
hand, Th2 cytokines (IL-4 and IL-10) have been shown to possess
antiinflammatory properties, neutralizing the effects of IFN-˜.
Mice tg for IL-10 are highly resistant to myelin oligodendrocyte
glycoprotein 35–55-induced EAE (42, 43). Because these synthetic
peptides induced dominant Th2 cytokines, these Th2 cytokines
presumably contributed to the reduction of disease severity in both
EAE models. Induction of cell death of antigen-specific T cells was
not a possibility because no nonspecific cell death was seen in
cultures treated with the synthetic peptides alone.
Thus, peptide 15-mers of defined sequence have been synthe-
sized that can substitute for random amino acid copolymers in the
amelioration of EAE. Three such copolymers have been described
as follows: viz., Copolymer 1 [YEAK, poly(Y,E,A,K)n]; FYAK,
[poly(F,Y,A,K)n]; and VWAK, [poly(V,W,A,K)n] (29, 30). Cop1 is
made in solution by polymerization of N-carboxy amino acid
anhydrides, whereas FYAK and VWAK were made by the more
recent solid phase chemistry. In either case, the precise constituents
of these random copolymer mixtures are not reproducible from
batch to batch. The length of the copolymers produced varies from
50 to 80 amino acids. Copolymers of 50 amino acids in length or
larger are biologically active. Considerable reduction in efficacy
occurs with copolymers of 35 amino acids in length and related
random peptides of 15 amino acids (slightly larger than the groove
in HLA-DR2 to which peptides and copolymers bind) are essen-
tially inactive (17). Based on the data presented here, a size of 50
or larger may be required to generate within the random copoly-
mers a specific sequence or sequences in sufficient quantity to
produce the desired effect. The present peptides and the three
copolymers appear to share the ability to induce the antiinflam-
matory cytokines IL-4 and IL-10. Among these, FYAK and pep-
tides J3 and J5 are the most effective in this respect. The minimum
similarity to MBP 85–99 and the lack of cross-reactivity with cell
lines specific for either MBP 85–99 or PLP 139–151 suggest that the
synthetic peptides described here may be suitable for clinical trials
in human subjects with MS.
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